Merck climbs on quarterly revenue beat
MRK•Year-to-date performance
** Up to last close, stock up 21.3% YTD
Shares rise after revenue beat
** Shares of drugmaker Merck MRK.N rise 2% to $130 premarket
** MRK's Q2 revenue of $16.61 billion beats analysts' average expectation of $16.38 billion, according to LSEG data
** Merck's quarterly results were helped by strong sales of cancer treatment Keytruda, powered by its newer subcutaneous formulation, Keytruda QLEX
Quarterly loss and acquisition charge
** Co reports Q2 adjusted loss of 13 cents/shr vs analysts' average loss estimate of 27 cents/shr
** MRK says the quarterly loss includes $2.31 per share charge from its acquisition of cancer drug developer Terns Pharmaceuticals
Related News
TKO Group Holdings Inc <TKO.N>: Morgan Stanley Raises Target Price to $230.00 From $225.00
TKO•
Central Bancompany FY26 Q2 net income climbs 24.5% to $113.77 million; net interest margin widens 8 percentage points to 4.4% vs prior quarter
CBC•
